… momentum toward the clinic Accelerated development of Axiomer™ for CNS applications via new research partnership … on RNA editing, ProQR made important progress with Axiomer, our ADAR-mediated RNA editing technology platform,” …
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indicationPipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical cataly
… transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the … appointments support the advancement of the Company’s Axiomer platform technology and pipeline of RNA editing …
… transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today reported its … ProQR and further supports the confidence we have in our Axiomer technology,” said Daniel A. de Boer, Founder and CEO … with meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides. Key data reported …
AX-0810 clinical target engagement data in healthy volunteers on track for this quarter; biliary atresia selected as initial Phase 2 indicationAdditional programs advancing toward the clinic, including AX-0811 and AX-0422Axiomer platform supporting multiple addi
… transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its … We look forward to providing additional updates on our Axiomer pipeline and platform progress at our Analyst and … Editing Summit in Boston, highlighting applications of its Axiomer RNA editing platform technology in CNS. In June, …